Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | BMY | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 47.77 | 0.00 | 0.00 | 0.00 | 47.77 | 04:16:42 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.00 | USD |
Bristol Myers Squibb Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 78.14B | 1.64B | $ 4.92B | 3.01 | 12.10 | 1.63B |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 124.02M | $ 0.41 | 0.86% | 07/03/19 | - | - |
Bristol Myers Squibb News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BMY Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 45.83 | 48.01 | 45.32 | 47.0912 | 8M | 1.94 | 4.23% |
| 1 Month | 42.9 | 48.01 | 41.79 | 45.8714 | 14M | 4.87 | 11.35% |
| 3 Months | 45.36 | 49.67 | 41.19 | 45.7451 | 13M | 2.41 | 5.31% |
| 6 Months | 50.44 | 54.38 | 41.19 | 47.3189 | 16M | -2.67 | -5.29% |
| 1 Year | 60.12 | 63.69 | 41.19 | 49.0270 | 13M | -12.35 | -20.54% |
| 3 Years | 59.65 | 70.05 | 41.19 | 53.0504 | 10M | -11.88 | -19.92% |
| 5 Years | 49.94 | 77.12 | 41.19 | 56.0574 | 8M | -2.17 | -4.35% |
Bristol Myers Squibb Description
| Bristol-Myers Squibb Co discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs. |
